In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?

被引:18
|
作者
Kulkarni, Smita Chinmay [1 ]
Sundaram, Palaniswamy Shanmuga [1 ]
Padma, Subramanyam [1 ]
机构
[1] Amrita Vishwavidyapeetham, Dept Nucl Med & Mol Imaging, Amrita Inst Med Sci, Kochi, Kerala, India
关键词
Gallium-68 prostate-specific membrane antigen; positron emission tomography-computed tomography; prostate neoplasm; prostate-specific antigen; magnetic resonance imaging; ACCURACY; NODES; MRI; CT;
D O I
10.1097/MNM.0000000000001110
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To assess the diagnostic performance of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography (Ga-68-PSMA PET-CT) in primary lymphnodal staging of patients with intermediate-risk and high-risk prostate cancer and to compare it with multiparametric MRI (mp-MRI) whenever available. Materials and methods Ga-68-PSMA PET-CT scans of 51 patients (average age 66.0 +/- 7.0 years) with biopsy-proven intermediate-risk and high-risk prostatic cancer who were managed by radical prostatectomy and extended pelvic lymph nodal dissection were retrospectively analyzed. Diagnostic performance of Ga-68-PSMA PET-CT in primary lymph nodal staging was analyzed using histopathology as reference. Diagnostic performance of mp-MRI, which was available in 35/51 patients was compared with that of Ga-68-PSMA PET-CT. Results Univariate analysis of patient characteristics showed significant influence of the pathological T-stage and maximum standard uptake value (SUV)max of the primary lesion on presence of nodal metastasis. In 51 patients, for patient-based analysis, the sensitivity, specificity and accuracy of Ga-68-PSMA PET-CT in detecting lymphnodal metastases were 80, 90.3 and 86.3%, respectively, and for lesion-based analysis 69.2, 99.6 and 98.4%, respectively. In 35/51 patients (who also had undergone mp-MRI), the patient-based and lesion-based sensitivity, specificity, and accuracy of Ga-68-PSMA PET-CT were 81.3, 84.2, 82.8% and 70.9, 99.5, 98.2%, respectively, and that of mp-MRI were 43.7, 78.9, 62.8% and 32.2, 98.5, 95.5%, respectively. For lesion-based analysis, Ga-68-PSMA PET-CT performed better than mp-MRI (P value = 0.04). Conclusion Ga-68-PSMA PET-CT allows accurate detection of lymphnodal metastases in patients with intermediate-risk and high-risk prostate cancer prior to definitive surgical treatment. It performed better than mp-MRI in a subset of patients.
引用
收藏
页码:139 / 146
页数:8
相关论文
共 50 条
  • [21] Risk of metastatic disease on 68gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer
    Yaxley, John W.
    Raveenthiran, Sheliyan
    Nouhaud, Francois-Xavier
    Samaratunga, Hemamali
    Yaxley, William J.
    Coughlin, Geoff
    Yaxley, Anna J.
    Gianduzzo, Troy
    Kua, Boon
    McEwan, Louise
    Wong, David
    BJU INTERNATIONAL, 2019, 124 (03) : 401 - 407
  • [22] Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis
    Kim, Seong-Jang
    Lee, Sang-Woo
    Ha, Hong Koo
    UROLOGIA INTERNATIONALIS, 2019, 102 (01) : 27 - 36
  • [23] Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer
    Haberkorn, Uwe
    Kopka, Klaus
    Hadaschik, Boris
    EUROPEAN UROLOGY, 2016, 69 (03) : 397 - 399
  • [24] Gallium-68 Prostate-Specific Membrane Antigen Positron Emission Tomography: A Practical Guide for Radiologists and Clinicians
    Manzil, Fathima Fijula Palot
    Kaur, Harleen
    Szabados, Lajos
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
  • [25] Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
    Kamaleshwaran, Koramadai Karuppusamy
    Balasundararaj, Barani Kumar Pollachi
    Jose, Raghi
    Shinto, Ajit Sugunan
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2018, 33 (01): : 57 - 58
  • [26] Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
    Xiang, Michael
    Ma, Ting Martin
    Savjani, Ricky
    Pollom, Erqi L.
    Karnes, R. Jeffrey
    Grogan, Tristan
    Wong, Jessica K.
    Motterle, Giovanni
    Tosoian, Jeffrey J.
    Trock, Bruce J.
    Klein, Eric A.
    Stish, Bradley J.
    Dess, Robert T.
    Spratt, Daniel E.
    Pilar, Avinash
    Reddy, Chandana
    Levin-Epstein, Rebecca
    Wedde, Trude B.
    Lilleby, Wolfgang A.
    Fiano, Ryan
    Merrick, Gregory S.
    Stock, Richard G.
    Demanes, D. Jeffrey
    Moran, Brian J.
    Huland, Hartwig
    Tran, Phuoc T.
    Martin, Santiago
    Martinez-Monge, Rafael
    Krauss, Daniel J.
    Abu-Isa, Eyad I.
    Alam, Ridwan
    Schwen, Zeyad
    Pisansky, Thomas M.
    Choo, C. Richard
    Song, Daniel Y.
    Greco, Stephen
    Deville, Curtiland
    McNutt, Todd
    DeWeese, Theodore L.
    Ross, Ashley E.
    Ciezki, Jay P.
    Boutros, Paul C.
    Nickols, Nicholas G.
    Bhat, Prashant
    Shabsovich, David
    Juarez, Jesus E.
    Chong, Natalie
    Kupelian, Patrick A.
    Rettig, Matthew B.
    Zaorsky, Nicholas G.
    JAMA NETWORK OPEN, 2021, 4 (12) : E2138550
  • [27] Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum
    Stranne, Johan
    Henry, Ann
    Oprea-Lager, Daniela E.
    EUROPEAN UROLOGY, 2025, 87 (02) : 108 - 109
  • [28] Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging
    Ma, Ting Martin
    Gafita, Andrei
    Shabsovich, David
    Juarez, Jesus
    Grogan, Tristan R.
    Thin, Pan
    Armstrong, Wesley
    Sonni, Ida
    Nguyen, Kathleen
    Lok, Vincent
    Reiter, Robert E.
    Rettig, Matthew B.
    Steinberg, Michael L.
    Kupelian, Patrick A.
    Yang, David D.
    Muralidhar, Vinayak
    Chu, Carissa
    Feng, Felix
    Savjani, Ricky
    Deng, Jie
    Parikh, Neil R.
    Nickols, Nicholas G.
    Elashoff, David
    Czernin, Johannes
    Calais, Jeremie
    Kishan, Amar U.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (01): : 100 - 103
  • [29] The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer
    Koschel, Samantha
    Murphy, Declan G.
    Hofman, Michael S.
    Wong, Lih-Ming
    CURRENT OPINION IN UROLOGY, 2019, 29 (06) : 569 - 577
  • [30] A comparison study of 68gallium-prostate-specific membrane antigen positron emission tomography-computed tomography and multiparametric magnetic resonance imaging for locoregional staging of prostate cancer
    Patel, Kartik Shashikant
    Singh, Tarun
    Raghuvanshi, Kshitij
    Sonar, Sameer
    Chaudhari, Rajeev
    UROLOGICAL SCIENCE, 2024, 35 (01) : 36 - 41